Sequential treatment with NOTCH inhibitor crenigacestat followed by pazopanib in soft tissue sarcoma patients.

Competing Interests: Disclosure OM has received consultancy fees from Bayer, Blueprint Medicines, Bristol-Myers Squibb, Eli Lilly, Ipsen, Janssen, Lundbeck, Merck Sharpe & Dohme, Pfizer, Roche, Servier, and Vifor Pharma. He is a shareholder of Amplitude Surgical, Ipsen, and Transgene. SW has declared no conflicts of interest. CM has received consultancy fees from Amgen, Astellas, Astra Zeneca, Bayer, BeiGene, Bristol-Myers Squibb, Celgene, Debiopharm, Genentech, Ipsen, Janssen, Lilly, MedImmune, Merck Sharpe & Dohme, Novartis, Orion, Pfizer, Roche, and Sanofi. ALC has received consultancy fees from Amgen, Bayer, Eli-Lilly, Novartis, PharmaMar, and Pfizer. KAB reports employment by Eli Lilly and stock holding of Eli Lilly; KAB has been a full-time employee of Taiho Oncology since January 2019. JCS has received consultancy fees from AstraZeneca, Astex, Clovis, GlaxoSmithKline, GamaMabs, Lilly, Merck Sharpe & Dohme, Mission Therapeutics, Merus, Pfizer, PharmaMar, Pierre Fabre, Roche/Genentech, Sanofi, Servier, Symphogen, and Takeda and has been a full-time employee of MedImmune from September 2017 to December 2019. He is a shareholder of AstraZeneca and Gritstone.